查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2135516

siRNA偶聯物市場：全球市場預測，2026-2032年

siRNA Conjugates Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，siRNA 偶聯物市場將成長至 9.8538 億美元，複合年成長率為 8.75%。

主要市場統計數據
基準年 2025 5.4762億美元
預計年份：2026年 6.0098億美元
預測年份 2032 9.8538億美元
複合年成長率 (%) 8.75%

siRNA綴合物：執行摘要

小干擾RNA (siRNA) 偶聯物是一種治療性偶聯物，其中RNA干擾的活性成分與標靶化配體或遞送組分融合。其價值提案在於選擇性組織遞送、持續基因靜默以及針對傳統藥物難以調控的疾病路徑進行治療的潛力。研發重點日益集中於標靶檢驗、偶聯物穩定性、核內體逃脫、給藥便捷性以及具有臨床意義的安全性。

遞送準確性正在重新思考siRNA偶聯物的開發。

研發重點正從驗證基因靜默轉向差異化的遞送能力和病患便利性。配體選擇、組織親和性、連接子化學、活性成分最佳化、生產一致性和生物標記策略等因素正日益成為緊密交織的研發決策。監管機構也高度重視可重複的表徵、免疫抗原性評估、脫靶效應評估以及動態效應能帶來持續臨床效益的證據。

人工智慧加速了設計、選擇和監控。

人工智慧可以透過對目標序列進行排序、預測分子間相互作用、識別潛在的脫靶效應、最佳化配體-連接子-有效載荷組合以及改進分析結果的解讀，來輔助siRNA偶聯物的研究。機器學習工具還可以透過整合轉錄組、蛋白質組和臨床數據來幫助最佳化患者選擇策略。然而，人工審核仍然至關重要，因為訓練資料的品質、生物學背景、模型的可解釋性以及前瞻性檢驗決定了計算建議的可靠性。

區域性洞察：功能和可用性因地區而異。

北美匯聚了先進的RNA療法研究、專業的臨床基礎設施和成熟的轉化網路。歐洲受益於強大的學術研究和協調的法律規範，而亞太地區正在不斷提升其在藥物發現、生產和臨床開發方面的能力。拉丁美洲在臨床實踐、專業知識和夥伴關係關係方面具有重要意義，儘管各國的基礎設施可能存在差異。中東正透過機構投資發展生物醫學和轉化研究能力，而非洲則因其未被滿足的需求以及在加強診斷、臨床試驗和供應鏈體系方面的實際需求而蘊藏著機會。

團體洞察：夥伴關係塑造研究與實施

東南亞國協擁有多元化的患者群體、臨床網路和製造夥伴關係，而金磚國家在科學、生產和醫療保健系統方面具備強大的實力，儘管其法規環境各不相同。歐盟支持跨境研究和監管協調。七國集團在生物技術、臨床科學和先進製造領域擁有深厚的專業知識。海灣合作理事會國家正在建立創新生態系統和專業醫療保健能力，而北約成員國則為研究、採購和醫療安全提供了廣泛的網路。在這些群體中，互通性和公平獲取標準仍然是關鍵的實際考量。

國家概況：各國在重點市場的獨特優勢

美國和加拿大擁有強大的轉化醫學生態系統和臨床開發能力。英國、法國、德國、義大利和西班牙在更廣泛的歐洲網路中擁有成熟的生物醫學研究、專科藥物和監管經驗。中國、日本、韓國、印度和澳洲提供重要的科學研究、生產和臨床資源，以及各自獨特的國家法規和報銷途徑。巴西和墨西哥是拉丁美洲重要的科學研究合作和臨床進入市場。俄羅斯在科學研究和醫療保健領域保持著一定的實力，但需要對其監管、營運和合作條件進行仔細評估。

siRNA偶聯物領域領導企業的優先事項

行業領導企業應選擇具有吸引力且基於人類生物學的靶點，根據靶組織和劑量分佈客製化偶聯物設計，並儘早建立轉化生物標記。研發計劃應整合序列最佳化、遞送技術、免疫抗原性測試、可擴展的分析方法以及基於風險的臨床監測。各組織應建構區域合格的證據和准入策略，驗證生產和物流合作夥伴，保護關鍵智慧財產權，並在受控工作流程下利用人工智慧，並進行獨立的生物學檢驗。儘早與監管機構、臨床醫生、患者和診斷相關人員進行溝通，有助於提高研發成果的實用化相關性和成熟度。

調查方法執行摘要

本綜述對siRNA偶聯物領域進行了結構化回顧，重點關注同行評審的研究、臨床和監管資料、技術文獻以及公開可獲取的遞送技術、生產製造、生物標記和醫療保健系統資訊。研究結果依主題整合，涵蓋技術、研發、區域、群體和國家層面。本評估避免了未經證實的數值論斷，並將監管成熟度、基礎設施、數據可用性和獲取條件方面的差異視為重要的不確定性來源。

結論：siRNA偶聯物的應用進展取決於實施品質。

siRNA偶聯物的發展得益於RNA生物學、標靶遞送、生物標記驅動的研發以及專業化生產技術的融合。持續進展與其說是取決於有效載荷本身的活性，不如說是取決於能否實現可預測的組織暴露、可控的安全性、實用的給藥方法、穩健的生產系統以及顯著的患者獲益。那些能夠將平台科學與嚴謹的臨床應用、可控的人工智慧、本地化適應性和負責任的准入計劃相結合的領導者，將更有能力把科學潛力轉化為可操作的療法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 siRNA偶聯物市場：依結合類型分類

  • Galnac
  • 脂質奈米顆粒
  • 胜肽

第8章：siRNA偶聯物市場：依治療領域分類

  • 心血管系統
  • 中樞神經系統
  • 慢性病
  • 腫瘤學
  • 罕見疾病

第9章：siRNA偶聯物市場：依研發階段分類

  • 臨床試驗
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的
  • 臨床前階段
    • 體外
    • 體內

第10章：siRNA偶聯物市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第11章 siRNA偶聯物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 siRNA偶聯物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：siRNA偶聯物市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Agilent Technologies Inc
  • Alnylam Pharmaceuticals Inc
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc
  • Bioneer Corporation
  • Dicerna Pharmaceuticals Inc
  • GenePharma Co Ltd
  • Ionis Pharmaceuticals Inc
  • Lonza Group AG
  • Merck KGaA
  • Olix Pharmaceuticals Inc
  • PharmaMar SA
  • Silence Therapeutics plc
  • Sirnaomics Inc
  • Thermo Fisher Scientific Inc
  • Wave Life Sciences Ltd

第16章 主要專家

Product Code: MRR-961F26FD6495

The siRNA Conjugates Market is projected to grow by USD 985.38 million at a CAGR of 8.75% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 547.62 million
Estimated Year [2026] USD 600.98 million
Forecast Year [2032] USD 985.38 million
CAGR (%) 8.75%

siRNA Conjugates: Executive Summary

Small-interfering RNA (siRNA) conjugates are therapeutic constructs that link RNA-interference payloads to targeting ligands or delivery components. Their value proposition centers on selective tissue delivery, durable gene silencing, and the potential to address disease pathways that are difficult to modulate with conventional medicines. Development priorities increasingly focus on target validation, conjugate stability, endosomal escape, dosing convenience, and clinically meaningful safety profiles.

Delivery Precision Is Reshaping siRNA Conjugate Development

The landscape is shifting from proof of gene silencing toward differentiated delivery performance and patient usability. Ligand selection, tissue tropism, linker chemistry, payload optimization, manufacturing consistency, and biomarker strategy are becoming tightly connected development decisions. Regulatory expectations also emphasize reproducible characterization, immunogenicity assessment, off-target evaluation, and evidence that pharmacodynamic effects translate into durable clinical benefit.

Artificial Intelligence Accelerates Design, Selection, and Monitoring

Artificial intelligence can support siRNA conjugate research by ranking target sequences, predicting molecular interactions, identifying potential off-target effects, optimizing ligand-linker-payload combinations, and improving analytical interpretation. Machine-learning tools may also help integrate transcriptomic, proteomic, and clinical data to refine patient-selection strategies. Human review remains essential because training-data quality, biological context, model interpretability, and prospective validation determine whether computational recommendations are reliable.

Regional Insights: Capabilities and Access Conditions Vary

North America combines advanced RNA therapeutics research, specialized clinical infrastructure, and established translational networks. Europe benefits from strong academic science and coordinated regulatory frameworks, while Asia-Pacific is expanding capabilities across discovery, manufacturing, and clinical development. Latin America is relevant for clinical access, specialist expertise, and partnerships, although infrastructure can vary by country. The Middle East is developing biomedical and translational capacity through institutional investment, and Africa presents both unmet-need opportunities and the practical requirement for strengthened diagnostic, trial, and supply-chain systems.

Group Insights: Alliances Shape Research and Adoption

ASEAN economies can contribute diverse patient populations, clinical networks, and manufacturing partnerships, while BRICS members bring substantial scientific, production, and healthcare-system capabilities with differing regulatory environments. The European Union supports cross-border research and regulatory coordination. G7 countries provide deep expertise in biotechnology, clinical science, and advanced manufacturing. GCC states are building innovation ecosystems and specialized healthcare capacity, and NATO members offer broad research, procurement, and health-security networks. Across these groups, interoperability of standards and equitable access remain important execution considerations.

Country Insights: Distinct Strengths Across Priority Markets

The United States and Canada offer strong translational ecosystems and clinical-development capabilities. The United Kingdom, France, Germany, Italy, and Spain contribute established biomedical research, specialist care, and regulatory experience within broader European networks. China, Japan, South Korea, India, and Australia provide significant scientific, manufacturing, and clinical resources, with country-specific regulatory and reimbursement pathways. Brazil and Mexico are important Latin American markets for research collaboration and clinical access. Russia retains scientific and healthcare capabilities but requires careful assessment of regulatory, operational, and collaboration conditions.

Action Priorities for siRNA Conjugate Leaders

Industry leaders should select targets with compelling human biology, align conjugate design with the intended tissue and dosing profile, and establish translational biomarkers early. Development plans should integrate sequence optimization, delivery engineering, immunogenicity testing, scalable analytical methods, and risk-based clinical monitoring. Organizations should build regionally adaptable evidence and access strategies, qualify manufacturing and logistics partners, protect critical intellectual property, and use artificial intelligence under governed workflows with independent biological validation. Early engagement with regulators, clinicians, patients, and diagnostic stakeholders can improve development relevance and adoption readiness.

Research Methodology for the Executive Summary

This summary uses a structured review of the siRNA conjugate field, emphasizing peer-reviewed research, clinical and regulatory materials, technical publications, and publicly documented information on delivery technologies, manufacturing, biomarkers, and healthcare systems. Findings were synthesized thematically across technology, development, regional, group, and country dimensions. The assessment avoids unsupported numerical claims and treats differences in regulatory maturity, infrastructure, data availability, and access conditions as material sources of uncertainty.

Conclusion: Execution Quality Will Define siRNA Conjugate Progress

siRNA conjugates are advancing through a combination of RNA biology, targeted delivery, biomarker-led development, and specialized manufacturing. Durable progress will depend less on payload activity alone than on achieving predictable tissue exposure, manageable safety, practical dosing, robust production, and evidence of meaningful patient benefit. Leaders that connect platform science with disciplined clinical translation, governed artificial intelligence, regional adaptability, and responsible access planning will be better positioned to convert scientific promise into usable therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. siRNA Conjugates Market, by Conjugate Type

  • 7.1. Introduction
  • 7.2. Galnac
  • 7.3. Lipid Nanoparticle
  • 7.4. Peptide

8. siRNA Conjugates Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular
  • 8.3. Central Nervous System
  • 8.4. Chronic Disease
  • 8.5. Oncology
  • 8.6. Rare Disease

9. siRNA Conjugates Market, by Development Stage

  • 9.1. Introduction
  • 9.2. Clinical Trials
    • 9.2.1. Phase I
    • 9.2.2. Phase II
    • 9.2.3. Phase III
  • 9.3. Commercial
  • 9.4. Preclinical
    • 9.4.1. In Vitro
    • 9.4.2. In Vivo

10. siRNA Conjugates Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Research Institutes
  • 10.4. Specialty Clinics

11. siRNA Conjugates Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. siRNA Conjugates Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. siRNA Conjugates Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Agilent Technologies Inc
  • 15.2. Alnylam Pharmaceuticals Inc
  • 15.3. Arbutus Biopharma Corporation
  • 15.4. Arrowhead Pharmaceuticals Inc
  • 15.5. Bioneer Corporation
  • 15.6. Dicerna Pharmaceuticals Inc
  • 15.7. GenePharma Co Ltd
  • 15.8. Ionis Pharmaceuticals Inc
  • 15.9. Lonza Group AG
  • 15.10. Merck KGaA
  • 15.11. Olix Pharmaceuticals Inc
  • 15.12. PharmaMar S.A.
  • 15.13. Silence Therapeutics plc
  • 15.14. Sirnaomics Inc
  • 15.15. Thermo Fisher Scientific Inc
  • 15.16. Wave Life Sciences Ltd

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global siRNA Conjugates Market, Years Considered for the Study
  • FIGURE 2. Global siRNA Conjugates Market, Research Design
  • FIGURE 3. Global siRNA Conjugates Market, Research Framework
  • FIGURE 4. Global siRNA Conjugates Market, Data Triangulation
  • FIGURE 5. Global siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global siRNA Conjugates Market Size, by Conjugate Type, 2025 vs 2032 (%)
  • FIGURE 7. Global siRNA Conjugates Market Size, by Conjugate Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global siRNA Conjugates Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 9. Global siRNA Conjugates Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global siRNA Conjugates Market Size, by Development Stage, 2025 vs 2032 (%)
  • FIGURE 11. Global siRNA Conjugates Market Size, by Development Stage, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global siRNA Conjugates Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global siRNA Conjugates Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global siRNA Conjugates Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global siRNA Conjugates Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global siRNA Conjugates Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global siRNA Conjugates Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global siRNA Conjugates Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global siRNA Conjugates Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global siRNA Conjugates Market Segmentation & Coverage
  • TABLE 2. Global siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 4. Global Galnac Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Galnac Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Galnac Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Lipid Nanoparticle Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Lipid Nanoparticle Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Lipid Nanoparticle Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Peptide Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Peptide Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Peptide Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 14. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Chronic Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Chronic Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Chronic Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Rare Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Rare Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Rare Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 30. Global Clinical Trials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Clinical Trials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Clinical Trials Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global In Vitro Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global In Vitro Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global In Vitro Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global In Vivo Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global In Vivo Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global In Vivo Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 55. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global siRNA Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Asia-Pacific siRNA Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Asia-Pacific siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 67. Asia-Pacific siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 68. Asia-Pacific siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 69. Asia-Pacific siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 70. Asia-Pacific siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 72. North America siRNA Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. North America siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 74. North America siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 75. North America siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 76. North America siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 77. North America siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 78. North America siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 79. Latin America siRNA Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Latin America siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 81. Latin America siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 82. Latin America siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 83. Latin America siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 84. Latin America siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 85. Latin America siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 86. Europe siRNA Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Europe siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 88. Europe siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 89. Europe siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 90. Europe siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 91. Europe siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 92. Europe siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 93. Middle East siRNA Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Middle East siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 95. Middle East siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 96. Middle East siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 97. Middle East siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 98. Middle East siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 99. Middle East siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 100. Africa siRNA Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Africa siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 102. Africa siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 103. Africa siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 104. Africa siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 105. Africa siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 106. Africa siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 107. Global siRNA Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. ASEAN siRNA Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. ASEAN siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 110. ASEAN siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 111. ASEAN siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 112. ASEAN siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 113. ASEAN siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 114. ASEAN siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 115. GCC siRNA Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. GCC siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 117. GCC siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 118. GCC siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 119. GCC siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 120. GCC siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 121. GCC siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 122. European Union siRNA Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. European Union siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 124. European Union siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 125. European Union siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 126. European Union siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 127. European Union siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 128. European Union siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 129. BRICS siRNA Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 130. BRICS siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 131. BRICS siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 132. BRICS siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 133. BRICS siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 134. BRICS siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 135. BRICS siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 136. G7 siRNA Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. G7 siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 138. G7 siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 139. G7 siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 140. G7 siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 141. G7 siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 142. G7 siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 143. NATO siRNA Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. NATO siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 145. NATO siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 146. NATO siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 147. NATO siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 148. NATO siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 149. NATO siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. Global siRNA Conjugates Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 151. United States siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 152. United States siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 153. United States siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 154. United States siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 155. United States siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 156. United States siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 157. United States siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 158. Canada siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 159. Canada siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 160. Canada siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 161. Canada siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 162. Canada siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 163. Canada siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 164. Canada siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 165. Mexico siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 166. Mexico siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 167. Mexico siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 168. Mexico siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 169. Mexico siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 170. Mexico siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 171. Mexico siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. Brazil siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 173. Brazil siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 174. Brazil siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 175. Brazil siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 176. Brazil siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 177. Brazil siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 178. Brazil siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 179. United Kingdom siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 180. United Kingdom siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 181. United Kingdom siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 182. United Kingdom siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 183. United Kingdom siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 184. United Kingdom siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 185. United Kingdom siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 186. Germany siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 187. Germany siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 188. Germany siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 189. Germany siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 190. Germany siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 191. Germany siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 192. Germany siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. France siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 194. France siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 195. France siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 196. France siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 197. France siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 198. France siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 199. France siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 200. Russia siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 201. Russia siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 202. Russia siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 203. Russia siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 204. Russia siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 205. Russia siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 206. Russia siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 207. Italy siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 208. Italy siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 209. Italy siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 210. Italy siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 211. Italy siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 212. Italy siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 213. Italy siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 214. Spain siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 215. Spain siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 216. Spain siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 217. Spain siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 218. Spain siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 219. Spain siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 220. Spain siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 221. China siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 222. China siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 223. China siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 224. China siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 225. China siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 226. China siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 227. China siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 228. India siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 229. India siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 230. India siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 231. India siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 232. India siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 233. India siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 234. India siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 235. Japan siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 236. Japan siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 237. Japan siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 238. Japan siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 239. Japan siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 240. Japan siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 241. Japan siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 242. Australia siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 243. Australia siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 244. Australia siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 245. Australia siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 246. Australia siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 247. Australia siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 248. Australia siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 249. South Korea siRNA Conjugates Market Size, 2017-2032 (USD Million)
  • TABLE 250. South Korea siRNA Conjugates Market Size, by Conjugate Type, 2017-2032 (USD Million)
  • TABLE 251. South Korea siRNA Conjugates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 252. South Korea siRNA Conjugates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 253. South Korea siRNA Conjugates Market Size, by Clinical Trials, 2017-2032 (USD Million)
  • TABLE 254. South Korea siRNA Conjugates Market Size, by Preclinical, 2017-2032 (USD Million)
  • TABLE 255. South Korea siRNA Conjugates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 256. Global siRNA Conjugates Market Share, by Key Player, 2025
  • TABLE 257. Global siRNA Conjugates Market, Key Experts